Company: BDRX
Filing Date: 2025-12-08
Form Type: F-1/A
Source: 0001214659-25-017719
Chunk: 25

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-08
Form: F-1/A
Chunk 25
---
 a way that does not yield a favorable,
or any, return for us. The failure of our management to use such funds effectively could have a material adverse effect on our business,
financial condition, operating results and cash flow.

The liquidity and trading volume of our Depositary Shares could be low.

The liquidity and trading
volume of our Depositary Shares has at times been low in the past and could again be low in the future. If the liquidity and trading volume
of our Depositary Shares is low, this could adversely impact the trading price of our shares, our ability to issue stock and our stockholders’
ability to obtain liquidity in their shares.

This is a best efforts offering, no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business plans, including our near-term business plans.

The Placement Agent has agreed to use its
reasonable best efforts to solicit offers to purchase the securities in this offering. The Placement Agent has no obligation to buy any
of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities. There is no
required minimum number of securities that must be sold as a condition to completion of this offering. Because there is no minimum offering
amount required as a condition to the closing of this offering, the actual offering amount, Placement Agent fees and proceeds to us are
not presently determinable and may be substantially less than the maximum amounts set forth above. We may sell fewer than all of the securities
offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive
a refund in the event that we do not sell an amount of securities sufficient to support our continued operations, including our near-term
continued operations. Thus, we may not raise the amount of capital we believe is required for our operations in the short-term and may
need to raise additional funds, which may not be available or available on terms acceptable to us.

This offering may result in an immediate trading halt or delisting of our Depositary Shares from NASDAQ due to public interest concerns.

Under NASDAQ Listing
Rule 5101, NASDAQ has broad discretionary authority to terminate the listing of securities, subject to a timely-requested hearing, if
it determines that continued listing is not in the public interest, even if the issuer is in compliance with NASDAQ’s enumerated
listing criteria. The Series L Warrants contain exercise price reset and share combination event provisions